

CURRICULUM VITAE
MOE, SHARON M. MD, FACP, FAHA, FASN

12/01/2006

EDUCATION

Undergraduate

University of Illinois at Urbana-Champaign
 Urbana, IL
 8/80 to 1/82 Degree: BS

Illinois State University
 Normal, IL
 8/78 to 6/80

Graduate

University of Illinois College of Medicine at Chicago
 Chicago, IL
 8/82 to 6/86 Degree: MD

Postdoctoral
 Research Fellow: 7/90 to 6/92
 Department of Medicine, Section of Nephrology
 University of Chicago, Chicago, IL

Clinical Fellow: 7/89 to 7/90
 Department of Medicine, Section of Nephrology
 University of Chicago, Chicago, IL

Intern and Resident 6/86 to 6/89
 Department of Internal Medicine
 Loyola University Medical Center, Maywood, IL

ACADEMIC APPOINTMENTS
(Indiana University School of Medicine)

Current:

Professor of Medicine (with tenure): 5/2005 to present
 Vice Chair for Research: 2/1/05 to present

Past:

Associate Professor of Medicine: (with tenure) 7/2001 to 5/2005
 Associate Dean for Research Support: 7/2003 to 2/1/05
 Assistant Dean for Research Support: 7/2001 to 7/2003
 Chief of Nephrology, Wishard Memorial Hospital: 1/98 to 2/2005
 Assistant Professor of Medicine: 7/95 to 6/2001
 Clinical Assistant Professor of Medicine: 7/92 to 6/95
 Member Graduate Faculty Indiana University Graduate School 2/2003 to present
 Director, Wishard Memorial Hospital Acute Dialysis Unit: 1/98 to 6/2001

Staff Physician

Indiana University Hospital (1992 to present)
 Wishard Memorial Hospital (1992 to present)
 Richard L. Roudebush Medical Center (Consultant 1992-1995; staff physician 1995 to present)
 Kindred Hospital of Indianapolis (1993 to present)
 Select Hospital of Indianapolis (2001 to present)

PROFESSIONAL CONSULTANTSHIPS

Genzyme RenaGel Physician Advisory Board, Jan 1998 to present
 Amgen, Inc. Consultant, 1998 to present
 Cytochroma, Inc. Advisory Board, 2005- present

SPECIALTY BOARD STATUS

National Board of Medical Examiners, 1986
 American Board of Internal Medicine, 1989
 American Board of Internal Medicine, Subspecialty in Nephrology, 1992, 2002

LICENSURE AND CERTIFICATIONS

State of Indiana # 920415 (current)
 State of Illinois #036-076622 (inactive)

PROFESSIONAL ORGANIZATIONS

American Society Nephrology

- Member, Post-Graduate Education Committee 1997 to 2000
- Member, Media Relations Task Force 2001 to 2003
- Fellow, 2005
- Member, Nominating Committee 2006
- Reviewer, American Society of Nephrology Annual Meeting Abstracts, 1998, 2000, 2004, 2006

National Kidney Foundation

- Member, National Kidney Foundation Kidney Disease Outcome Quality Initiative (KDOQI), Bone and Mineral Disease Working Group, 2001 to 2003
- Annual Scientific Meeting Planning Committee 1999 and 2000, Co-Chair 2004, Chair 2005

Kidney Disease Improving Global Outcomes (KDIGO)

- Co-Chair, National Kidney Foundation Global Mineral and Bone Initiative 2003 to present
- Member, Executive Committee KDIGO (Kidney Disease Improving Global Outcomes)- 2004 to present
- Co-Chair, KDIGO mineral and bone guidelines, 2006- present

International Society of Nephrology

- Councilor, representing U.S.A.- 2005-present

Women in Nephrology

- Co-Director, Professional Development Symposium, 2000-2002
- Counselor, 2003-present

National Kidney Foundation of Indiana

- Member, Board of Directors, 2000 to present
- Annual Gala Planning Committee, 1998-present
- Member, Medical Advisory Board

American Heart Association

- Executive Committee of the Council on the Kidney in Cardiovascular Disease (Counselor at large) 2002-2004
- Member, Kidney Council, 1998
- Fellow 2003

American College of Physicians, 1989 to present; fellow 2002

American Society for Bone and Mineral Research

International Bone and Mineral Society

EDITORIAL BOARDS

- American Journal of Kidney Diseases- Associate Editor, 2002-2004
- Advances in Renal Replacement Therapy- Editorial Board, 2003-present
- Journal of the American Society of Nephrology, 2004-present

REVIEWER

- Reviewer, American Society of Bone and Mineral Research Renal Osteodystrophy Working Group Abstracts, 1996-present
- Grant Reviewer for the National Kidney Foundation of Illinois and University of Louisville Foundation and Veterans Administration Merit Review Program, Israeli Diabetes Association, 2004-2005
- Reviewer for American Journal of Kidney Diseases, Journal of the American Society of Nephrology, Kidney International, Journal of the American Society for Bone and Mineral Research, Amyloidosis, Diabetes Care, JASN, Nephron, Clinical Nephrology, Nephrology, Dialysis and Transplantation, JCEM, American J Physiology

STUDY SECTIONS/NIH COMMITTEES

- Member, National Institute of Health, Protein production, structure, and function study section, SSS2, CSR, 1998, 1999
- “Experience Reviewer Reserve” NIH-NIDDK, 2003-present
- Ext Advisory committee, NIDDK HALT-PKD, 2005 to current
- DSMB, NIDDK HALT-PKD, 2005 to current
- Ad Hoc reviewer, NIH- NIAMS Loan Repayment, 2006
- Ad Hoc reviewer, NIH- ZRG1 MOSS-B, skeletal biology, 2006
- Ad Hoc reviewer, NIH- ZRG1- RUS-A, R21 NIDDK, 2006

LEADERSHIP IN SYMPOSIUMS/WORKSHOPS, ORGANIZING COMMITTEES

- Indiana University Faculty Clinical Research Training Seminar, annual seminar, organizer/moderator, 1998-present
- Indiana University Research Coordinator Education Program, a bi-annual program, organizing committee, 1999-present
- National Institutes of Health, NIDDK, “Planning a Career in Clinical Research”, organizing committee 2000, 2004
- National Kidney Foundation Annual Scientific Meeting Planning Committee, 1999, 2000
- American Society of Nephrology Professional Development Seminar co-moderator/organizer 1998-2001, moderator 2002
- Indiana University Annual Grant Writing Symposium, organizer, 2001 to present
- Accountability in Clinical Research: Balancing Risk and Benefit, national meeting by National Patient Safety Foundation, April 24-26, 2002, Indianapolis, IN-organizing committee
- National Kidney Foundation KDOQI (Kidney Disease Outcome Quality Initiative) Bone and Mineral Working Group, Member, 2001-2003
- National Kidney Foundation Controversies in Bone and Mineral Metabolism International Conference, 2003, co-moderator, Washington, DC
- American Society of Nephrology Annual Scientific Meeting Program Committee, 2003 meeting
- KDIGO, Diagnosis, Classification, and Evaluation International meeting, September, 2005 Madrid, Spain, Co-chair
- National Kidney Foundation (NKF) Annual Scientific Meeting Planning Committee Co-Chair 2004- Chicago, IL, Chair 2005- Washington DC
- Session chair/organizer, American Society for Bone and Mineral Research Annual Scientific Meeting, 2005
- KDIGO: International Clinical Practice Guidelines for Mineral and Bone Disease, Co-chair, 2006- present
- International Society of Nephrology: Nexus meeting: Bone and the Kidney, scientific planning committee for October 2006, meeting in Copenhagen Denmark

HONORS AND AWARDS

- Volunteer Service Award, National Kidney Foundation of Indiana, 1998
- Travel Award Recipient XII Annual Meeting of the International Council on Calcium Regulating Hormones, Melbourne, Australia, February 14-19, 1995
- Travel Award Recipient XI Annual Meeting of the International Council on Calcium Regulating Hormones, Florence, Italy, 1992
- Chairman’s Award, National Kidney Foundation, 2001, for Outstanding Contribution to Research Goals of NKF Indiana
- Outstanding Young Investigator, Department of Medicine, 2001
- Outstanding Nephrology Teacher, Department of Medicine, Division of Nephrology, 2003 (voted on by trainees)

- Endowed Lecture Recipient, Royal College of Physicians, Edinburgh, Scotland, 2004
- Trustee Teaching Award, Indiana University School of Medicine, 2003-04 (voted on by medical students)
- Elected to **American Society for Clinical Investigation (ASCI), 2005**

INVITED LECTURES AT INTERNATIONAL AND NATIONAL MEETINGS AND VISITING PROFESSORSHIPS

November 3, 1995: “Renal Osteodystrophy: Do We Need a Different Approach in Women?”, a lecture at the National Kidney Foundation 45th Annual Scientific Meeting, San Diego, CA

November 4, 1996: “Literature Review in Dialysis- Renal Osteodystrophy”, a lecture for a symposium at the American Society of Nephrology 29th Annual Meeting, New Orleans, LA

August 25, 1997: “Calcium and Phosphorus Metabolism”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 26, 1997: “Renal Osteodystrophy”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 31, 1998: “Calcium and Phosphorus Metabolism”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 31, 1998: “Disorders of Calcium and Phosphorus”, a workshop for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

September 1, 1998: “Diagnosis of Bone Disease-Radiology and Biopsy”, a workshop for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

September 1, 1998: “Renal Osteodystrophy”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

October 24, 1998: “ESRD Osteodystrophy”, a lecture for the American Society of Nephrology Annual Meeting Postgraduate Education Course: The Principles and Practice of Hemodialysis: Reviews, Updates and Demonstrations

October 27, 1998: “Literature Update: Renal Osteodystrophy and Divalent Ion Metabolism- β -2-microglobulin Amyloidosis”, a lecture for Clinical Nephrology Symposia at the American Society of Nephrology Annual Meeting

May 1, 1999: “Recent Advances in Bone disease Therapies”, National Kidney Foundation Eight Annual Clinical Nephrology Meeting, Washington DC

August 29, 1999: “Renal Osteodystrophy”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 30, 1999: “Calcium and Phosphorus Metabolism”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 30, 1999: “Disorders of Calcium and Phosphorus”, a workshop for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 31, 1999: “Diagnosis of Bone Disease-Radiology and Biopsy”, a workshop for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

September 15, 1999: “Gender Difference in Bone Diseases in Patients with Renal Failure”, NIH special symposium entitled “Women and Renal Disease”, Bethesda, MD

November 6, 1999, Moderator, Clinical Nephrology Symposium: “Renal Osteodystrophy: New Insights into Pathogenesis and Treatment”, 32nd Annual Meeting of the American Society of Nephrology, Miami Beach, FL

November 6, 1999: “The Calcium X Phosphorus Product and the Relationship to Soft Tissue Calcification”, 32nd Annual Meeting of the American Society of Nephrology, Miami Beach, FL

April 14, 2000: “Calciophylaxis”, at the National Kidney Foundation Annual Meeting, Atlanta, GA

April 14, 2000: Clinical-pathologic conference “Renal Osteodystrophy”, Session Moderator at the National Kidney Foundation Annual Meeting, Atlanta, GA

April 14, 2000: “Clinical Bone Disease”, Session Moderator at the National Kidney Foundation Annual Meeting, Atlanta, GA

April 14, 2000: “Advances in PTH and Vitamin D Metabolism”, Session Moderator at the National Kidney Foundation Annual Meeting, Atlanta, GA

August 28, 2000: “Renal Osteodystrophy”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 28, 2000: “Calcium and Phosphorus Metabolism”, a lecture for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 29, 2000: “Disorders of Calcium and Phosphorus”, a workshop for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

August 29, 2000: “Diagnosis of Bone Disease-Radiology and Biopsy”, a workshop for the American Society of Nephrology Annual Board Review Course, San Francisco, CA

September 9, 2000: “Institutional Review Boards”, at the NIH/NIDDK symposium on Training for a Career in Clinical Research, Bethesda, MD

October 4, 2000: “Funding Opportunities”, at the Professional Development Seminar, held as a pre-course at the American Society of Nephrology 33rd Annual Meeting, Toronto, Canada

October 6, 2000: “Vascular Calcification”, at the American Society of Nephrology 33rd Annual Meeting, Toronto, Canada

April 21, 2001: “Bones, Hormones and ESRD”, at the National Kidney Foundation Annual Scientific Meeting, Orlando, FL

June 29, 2001: “Current Issues in the Management of Secondary Hyperparathyroidism/Bone Disease”, at the IX Congress of the International Society for Peritoneal Dialysis, Montreal, Canada

August 28, 2001: “Renal Osteodystrophy”, a lecture for the American Society of Nephrology Annual Board Review Course, Chicago, IL

August 27, 2001: “Calcium and Phosphorus Metabolism”, a lecture for the American Society of Nephrology Annual Board Review Course, Chicago, IL

August 28, 2001: “Disorders of Calcium and Phosphorus”, a workshop for the American Society of Nephrology Annual Board Review Course, Chicago, IL

- August 28, 2001: “Diagnosis of Bone Disease-Radiology and Biopsy”, a workshop for the American Society of Nephrology Annual Board Review Course, Chicago, IL
- September 8-9, 2001: “IRB” and “Planning for a Research Career”, for the NIH-NIDDK symposium “Preparing for a Clinical Research Career in Nephrology”, Bethesda, MD
- October 13, 2001: “Funding Your Research”, for the Professional Development Seminar at the American Society of Nephrology Annual Scientific Meeting, San Francisco, CA
- October 14, 2001: “Osteoporosis”, for an evening symposium entitled “Updates in Renal Osteodystrophy” at the American Society of Nephrology 34th Annual Meeting, San Francisco, CA
- October 15, 2001: “Vascular Calcification”, at the American Society of Nephrology 34th Annual Meeting, San Francisco, CA
- November 30, 2001: “Vascular Calcification in Dialysis”, at the 14th Annual Berliner Dialyseseminar, Berlin, Germany
- March 18, 2002: “Vascular Cell Impersonation of Osteoblasts”, at the Canadian Society of Nephrology, Ottawa, Canada
- March 30, 2002: “Vascular Calcification”, at the 11th International Congress on Nutrition and Metabolism in Renal Disease, Nagoya, Japan
- October 31, 2002: Coordinated and moderated Professional Development Pre-Course for the American Society of Nephrology Annual Scientific Meeting
- October 31, 2002: “Funding Your Research”, at the Professional Development Symposium
- November 2, 2002: “Basic Science of Dystrophic Calcification”, at the American Society of Nephrology Annual Scientific Meeting
- November 2, 2002: “Bone and Mineral Metabolism K/DOQI”, at the American Society of Nephrology Annual Scientific Meeting
- November 3, 2002: Moderated “Debates in Renal Failure-Renal Osteodystrophy”, at the American Society of Nephrology Annual Scientific Meeting
- April 3, 2003: “Management of Hyperparathyroidism in CKD”, at Symposium “Improving Outcomes in Anemia in Secondary Hyperparathyroidism”, at the National Kidney Foundation Annual Clinical Meetings, Dallas, Texas
- April 4, 2003: “Review of the New K/DOQI Guidelines for Managing Bone and Mineral Metabolism and Dyslipidemias in CKD; Disciplinary Team Approach, as part of a symposium “Practical Applications of the New K/DOQI Clinical Practice Guidelines”, National Kidney Foundation Annual Clinical Meetings, Dallas, Texas
- April 5, 2003: “Controlling Serum Phosphorus, K/DOQI Guidelines 3, 4, and 5”, at the National Kidney Foundation Annual Clinical Meetings, Dallas, Texas
- April 5, 2003: “The Future of Bone Disease Management”, National Kidney Foundation Annual Clinical Meetings, Dallas, Texas
- April 5, 2003: “Cellular Mechanisms of Vascular Calcification”, at symposium “Modern Management of Hyperphosphatemia”, at the National Kidney Foundation Annual Clinical Meetings, Dallas, Texas
- June 9, 2003: “K/DOQI Guidelines and Bone Disease Management”, World Congress of Nephrology, Berlin, Germany
- June 9, 2003: “Calciphylaxis and cardiovascular Risk”, World Congress of Nephrology, Berlin, Germany

- June 10, 2003: “New Insights in Bone Biology and Bone Disease; the Roles of Hormones, Growth Factors and Cytokines”, World Congress of Nephrology, Berlin, Germany
- November 13, 2003: “Renal Osteodystrophy in the Course “Peritoneal Dialysis” at the 36th Annual American Society of Nephrology, San Diego, California
- November 14, 2003: “Vitamin D and the Prevention of Morbidity and Mortality in Dialysis Patients-“Overview of Vitamin D Biology” at the 36th Annual American Society of Nephrology Annual Meeting, San Diego, California
- April 28, 2004: “Renal Osteodystrophy” at the 2004 National Kidney Foundation Clinical Meetings, Chicago, IL
- April 29, 2004: “Review of Current Therapeutic Strategies and Treatment Goals – NKF K/DOQI” at the 2004 National Kidney Foundation Clinical Meetings, Chicago, IL
- May 1, 2004: “Vascular Calcification” at the 2004 National Kidney Foundation Clinical Meetings, Chicago, IL
- May 2, 2004: “Pathophysiology of Renal Osteodystrophy” at the 2004 National Kidney Foundation Clinical Meetings, Chicago, IL
- June 1, 2004: “Uremic Vascular Calcification” endowed lecture at the Renal Medicine Symposium, the Royal College of Physicians of Edinburgh, Edinburgh, Scotland
- June 10, 2004: “Vascular Calcification” for Network 9 Annual Professional Meeting, Chicago, IL
- July 10-11, 2004: “Preparing for a Career in Clinical Research in Kidney and Urologic Diseases” National Institutes of Health/NIDDK, committee planning member and speaker
- September 17-18, 2004: “The relationship between vascular calcification and renal osteodystrophy” and “Update and new insights from the K/DOQI guidelines” at the National conference on Vascular Calcification”, Toronto, Canada
- October 28, 2004 “Vascular calcification and calciphylaxis” as part of the post graduate education course on complication of dialysis at the American Society of Nephrology Annual Scientific Meeting
- October 29, 2004 Moderator for session “Atherosclerosis: a different disease in CKD than in the general population” at the American Society of Nephrology Annual Scientific Meeting
- October 30, 2004 “Preventing complication of Mineral and Metal Accumulation in a Closed System” at the American Society of Nephrology Annual Scientific Meeting
- October 31, 2004 “Medical Cross-fire: An expert panel debates key clinical issues in managing bone and mineral metabolism in CKD” at the American Society of Nephrology Annual Scientific Meeting
- January 21, 2005 “Inflammation and Vascular Calcification” at the VIIth International conference on Dialysis, New Orleans, LA
- February 3, 2005 “Renal Osteodystrophy” at the Royal Free College of Medicine, London, UK
- February 4, 2005 “Cellular Mechanisms of Vascular Calcification” at the 5th International Workshop on Structure and Function of Large Arteries, Paris, France
- February 28, 2005 “Vascular Calcification” at the 25th Annual Dialysis Conference, Tampa FL
- March 1, 2005 “Secondary Hyperparathyroidism” at the 25th Annual Dialysis Conference, Tampa FL
- March 1, 2005 “PTH assays and Calcimimetics” at the at the 25th Annual Dialysis Conference, Tampa FL

May 4, 2005 “Cases in Mineral Metabolism”, at the NKF Annual Scientific Meeting, Washington DC

May 5, 2005 “Do the K/DOQI targets matter?” at the NKF Annual Scientific Meeting, Washington DC

May 7, 2005 “Evidence Based Practice of Nephrology: Global Bone and Mineral Initiative”, NKF Annual Scientific Meeting, Washington DC

June 28, 2005 “Treating secondary hyperparathyroidism”, World Congress of Nephrology, Singapore

October 11, 2005 Visiting Professor and “Vascular calcification” at Evanston Healthcare Northwestern, Evanston, IL

November 8, 2005 “Vascular calcification and Cardiovascular disease” American Society of Neph Annual Meeting, Philadelphia PA

November 8, 2005 “Practical and Ethical Issues of Pharmaceutical Trials” American Society of Neph Annual Meeting, Philadelphia PA

November 8, 2005 “Funding Opportunities and Goals” American Society of Neph Annual Meeting, Philadelphia PA

November 9, 2005 “Vascular calcification and calciphylaxis” American Society of Neph Annual Meeting, Philadelphia PA

November 10, 2005 “Medical Crossfire” American Society of Neph Annual Meeting, Philadelphia PA

December 13-14, 2005 Guest speaker at NKF Symposium and Visiting Professor at Temple University, Philadelphia, PA

January 25, 2006 “Treatment of CKD-Mineral and Bone Disorder” for the Japanese Society for Kidney Bone Disease, Tokyo, Japan

April 19, 2006 “Treatment of secondary hyperparathyroidism”, National Kidney Foundation Annual Scientific Meeting, Chicago, IL

September 29, 2006 “Treatment of CKD-MBD” New York City Annual Dialysis Conference, New York New York

October 10, 2006 “The new renal osteodystrophy- CKD-MBD” International Society of Nephrology, The Bone and Kidney meeting, Copenhagen Denmark

November 14, 2006 “Finding Funding Opportunities” American Society of Nephrology Annual Meeting, Professional Development Course, San Diego, CA

November 14, 2006 “KDIGO-CKD-MBD” American Society of Nephrology Annual Meeting, Clinical Pre-Course, San Diego, CA

November 14, 2006 “Vascular Calcification as a Cardiovascular Risk Factor” American Society of Nephrology Annual Meeting, , San Diego, CA

November 14, 2006 “Treating vascular calcification and renal osteodystrophy” American Society of Nephrology Annual Meeting, San Diego, CA

November 14, 2006 “Treating secondary hyperparathyroidism” American Society of Nephrology Annual Meeting, San Diego, CA

December 5, 2006 “Vitamin D and cardiovascular mortality in CKD” American Society for Bone and Mineral Research satellite symposium on vitamin D, Washington DC,

UNIVERSITY ADMINISTRATIVE SERVICE

Associate Director, Renal Fellowship Program, July 1994 to January 1998

Director, Department of Medicine Clinical Trials Program, September 1997 to present, a new program designed to facilitate clinical research and to market the physicians of the Department of Medicine.

Associate Dean for Research Support, Indiana University School of Medicine (Assistant Dean 2001 to 2003, Associate Dean 2003 to 2/2005). Oversee research education and compliance for the school of medicine.

Vice-Chair for Research, Department of Medicine February 2005- present

UNIVERSITY COMMITTEE SERVICE

- Chairperson, Animal Use Subcommittee, Roudebush Veterans Administration Hospital (Member 1995-1996; Chairperson 1997-2000), successfully converted probationary to approved status by AALAC for Animal Program at the VA
- Chairperson, Medicine Clinics Research Committee, 1998-2002. Wishard Hospital Committee that oversees clinical research efforts at Wishard Hospital
- Member, Indiana University Human Subjects Research Training and Education Task Force, 1999- 2002. Committee that has developed and oversees web based testing on human subject's protection
- Medical Director, Wishard Memorial Hospital Clinical Research Unit, 1999-2001
- Member, Institutional General Clinical Research Center Advisory Committee, 1996-1998
- Member, Institutional Review Board, Exempt/Expedited Review Committee, 2000-present, Chair 2005-present
- Member, Search and Screen Committee, Chief of Radiology at Roudebush VAMC, 1999-2000
- Member, Search and Screen Committee, Department of Medicine Chair, 2000
- Member, Task Force on Human Subjects Protection, 2000- 2005
- Member, Task Force on HIPAA Implementation, 2001- 2004
- Member, Search and Screen Committee, School of Medicine Compliance Officer, 2003
- Chairperson, IUPUI Human Subjects Research Committee, 2002-2004
- Member, School of Medicine Task Force for Strategic Plan for Clinical Research, 2003-2004
- Member, School of Medicine 3D design for research committee, 2003-2004
- Member, Department of Radiology Research Advisory Committee 2005
- Member, School of Medicine Research Task Force, 2005-2006
- Member, Clarian Transplant Institute Planning Committee, 2006 to present
- Member, Department of Medicine Promotion and Tenure Committee, 2006 to present
- Member, GI Chief search and screen committee, 2006 to present
- Chair, General Clinical Research Medical Advisory Committee, 2007- present

GRANTS, FELLOWSHIPS, AND AWARDS

Current

4/1/06 to 3/31/11: Principal Investigator, National Institutes of Health K-24 Award, \$511,827 total costs "Musculoskeletal Disorders in Dialysis Patients"

10/1/03 to 9/30/08: Principle Investigator, Veterans Administration Merit Review, \$678,500 total costs, "The role of Cbfa1 in Vascular Calcification and Osteoporosis in ESRD"

06/01/04 to 05/30/07: Principal Investigator, Amgen \$221,856 total costs "Prevention of bone disease and vascular calcification with sevelamer in a naturally occurring rodent model of polycystic kidney disease"

06/01/04 to 05/30/07: Principal Investigator, Genzyme \$132,682 total costs "Prevention of bone disease and vascular calcification with cinacalcet in a naturally occurring rodent model of polycystic kidney disease"

01/01/06-1/1/07 Principal Investigator, Genzyme \$97,780 “A randomized, parallel, open-label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride table dosing in CKD patients on hemodialysis”

Current Grants as Mentor:

7/1/03 to 6/30/08: Faculty Mentor (Principal Investigator Neal Chen, PhD) National Institutes of Health K-01 Award, “The Role of Cbfa1 in Vascular Calcification in Diabetes”

7/1/04 to 6/30/07: Faculty Mentor (Principal Investigator Anupama Mohanram, MD) American Diabetes Association Junior Faculty Award “Anemia in CKD”

7/1/05 to 6/3/10: Faculty Mentor (Principal Investigator Allon Friedman, MD), National Institutes of Health, K23 Award, “The Role of Obesity in CKD”

2/1/06 to 1/31/07: Faculty Mentor (Principal Investigator is Nephrology Trainee Akber Saifullah, MD), National Kidney Foundation of Indiana, \$10,000 “A randomized study comparing cholecalciferol versus doxercalciferol for secondary hyperparathyroidism in CKD stage 3 and 4 patients”, and GCRC CREFF award \$20,000

12/1/06 to 11/30/07: Faculty Mentor (Principal Investigator Brian Decker, MD), GCRC CREFF award \$20,000 “Drug dosing in daily dialysis”

Past

Investigator Initiated:

10/1/03 to 6/30/06: Co-Investigator, (Principal Investigator Neal Chen, PhD) Genzyme Therapeutics, \$150,000 total cost, “The Role of Fetuin and BMP-2 in Vascular Calcification in CKD-V Patients”

02/02/04 to 02/01/05: Principal Investigator Abbott Laboratories \$26,400 total costs, “The role of calcitriol and paricalcitol in vascular calcification.

03/01/00 to 2/28/05: Principal Investigator, National Institutes of Health K-24 Award, \$521,097 total costs “Musculoskeletal Disorders in Dialysis Patients”

7/1/01 to 6/30/03: Principal Investigator, American Heart Association Midwest Affiliate Research Award \$110,000 total costs “Phosphorus induces bone protein expression in vascular smooth muscle cells”

4/1/98 to 3/31/03: Principal Investigator, Veterans Administration Merit Review, \$349,000 total amount “Synovial Fibroblasts and Adhesion Molecules in Dialysis Amyloidosis”

2/1/01 to 1/31/02: Principal Investigator, National Kidney Foundation of Indiana, \$10,000 total costs “The natural history of coronary artery calcification in renal transplant recipients”

12/1/00 to 11/31/02: Co-Investigator, Diabetes and Research Training Center D/F grant \$48,000 total costs “Role of phosphorus in vascular calcification in diabetes”. Neal Chen, PhD, PI

12/1/98 to 1/1/01: Principal Investigator of Investigator Initiated study from Abbott Laboratories, “An evaluation of the effects of Zemplar supplementation on immune system parameters in hemodialysis patients with low parathyroid hormone levels”, \$120,000 total costs

3/15/95 to 2/29/00: Principal Investigator, National Institutes of Health K-08 Clinical Investigator Award, \$490,835 total costs “The role of synoviocytes in β_2 -microglobulin amyloidosis”

1/1/95 to 12/31/97: Principal Investigator, American Diabetes Association, \$98,980 total costs, “The role of glycosylated proteins in diabetic bone disease”

2/95 to 1/96: Principal Investigator, National Kidney Foundation of Indiana Grant, \$1,800 total costs, “The effect of glycosylated proteins on the pathogenesis of adynamic bone disease”

4/93 to 6/30/95: Principal Investigator, Indiana University Biomedical Research Grant, \$11,000 total costs “The evaluation of the frequency and route of optimal calcitriol administration for secondary hyperparathyroidism in patients receiving continuous ambulatory peritoneal dialysis”

Pharmaceutical sponsored Multi-Center Trials:

5/3/03 to present: Principal Investigator, Abbott Laboratories “A Phase IV, prospective, randomized, active-controlled, double-blind, double-dummy, multi-center study to evaluate the survival benefits of Zemplar relative to Calcijex in subjects with stage V chronic kidney disease on hemodialysis”. \$50,000 total costs

5/1/04 to present: A Phase IIIb, multi-center, 2 cohort, randomized study, with an open label run-in and a long term extension phase, assessing an extended dose range of lanthanum carbonate in end stage renal disease subjects receiving hemodialysis. \$35,000 total costs

5/1/05 to present: A double-blind, cross-over design study of sevelamer hydrochloride (Renagel®) and sevelamer carbonate in chronic kidney disease patients on hemodialysis (Genzyme Protocol No. GD3-163-201), \$50,000 total costs

2/1/01 to 8/2002: Principal Investigator, Amgen, Inc. \$56,400 total costs (Wishard Foundation) “A randomized, double-blind placebo controlled study to assess the safety and efficacy of a calcimimetic agent (AMG073) in subjects with secondary hyperparathyroidism of chronic renal insufficiency”

1/1/02 to 8/1/02: Principal Investigator, Abbot Laboratories, Inc., \$47,418 total costs, “A phase III, prospective, placebo controlled, double blind, randomized, multi-center study to evaluate the safety and efficacy of Zemplar capsules in reducing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis”

09/01/02 to 12/31/03: Principal Investigator, Geltex Pharmaceuticals/MedPace \$57,020 total costs “A randomized, open label, parallel design study of sevelamer hydrochloride (renagel) in chronic kidney disease patients”

12/14/01 to 12/31/02: Principal Investigator, Amgen, Inc, \$23,813 total costs, “A phase III study to assess the efficacy and safety of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of end stage renal disease treated with hemodialysis”

9/1/00 to 7/1/04: Principal Investigator, Amgen, Inc., “A multi-center, open label extension study to assess the long-term safety and efficacy of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of end-stage renal disease \$38,750 total costs

6/29/00 to 6/30/03: Principal Investigator, Amgen, Inc., \$28,139 total costs, “A multi-center, open label extension study to assess the long term safety and efficacy of an oral calcimimetic agent in secondary hyperparathyroidism of end stage renal disease”

6/23/99 to 9/30/00: Principal Investigator: Amgen, Inc., “A double-blind, randomized, placebo-controlled, multi-center study to assess the safety and efficacy of an oral calcimimetic agent (AMG073) in secondary hyperparathyroidism of end-stage renal disease (ESRD). \$108,563 total costs

6/15/99 to 3/31/00: Principal Investigator: Amgen, Inc. “A double-blind, multi-center trial to evaluate bone histomorphometry of ESRD subjects treated with AMG073 or placebo” \$17,055 total costs

7/1/99 to 6/30/00: Principal Investigator of Investigator Initiated study from Geltex Pharmaceuticals, “Sevelamer hydrochloride as a treatment for CAPD patients with low-turnover bone disease” \$72,882 total costs

8/92 to 12/93: Co-Investigator, Baxter Healthcare Corporation, \$66,822 total costs “Dianeal with 1.1 % Amino acids in malnourished continuous ambulatory peritoneal dialysis (CAPD) patients, Phase III trial”. Dr. Richard Hamburger, Principal Investigator

Past Grants (Faculty Sponsor)

2/1/05 to 1/31/06: Faculty Mentor, (Principal Investigator is Nephrology Trainee Rob LaClair, MD), National Kidney Foundation of Indiana, \$12,000 “Fetuin-a levels in hemodialysis patients: a longitudinal and comparison study”

2/1/00 to 1/31/01: National Kidney Foundation of Indiana Grant, \$7,883 total costs, “Vascular calcification of ESRD”. Dr. Sadiq Ahmed, Nephrology Fellow, Principal Investigator

1/1/99 to 12/31/99: National Kidney Foundation of Indiana Grant, \$2,500 total costs, “Increased expression of adhesion molecules ICAM-1 and VCAM-1 by beta-2-microglobulin in dialysis related amyloidosis. Dr. Majd Jaradat, Nephrology Fellow, Principal Investigator

2/94 to 1/95: National Kidney Foundation of Indiana Grant, \$1,350 total costs, “The effect of metabolic acidosis on the ability of calcitriol to correct the parathyroid hormone det point in hemodialysis patients”. Dr. Rosemary Ouseph, Nephrology Fellow, Principal Investigator

2/94 to 11/94: National Kidney Foundation of Indiana Grant, \$7,500 total costs, “The relationship between renal phosphate threshold and calcitriol levels in well-functioning renal allografts immediately post transplant”. Dr. Barbara Haehner, Nephrology Fellow, Principal Investigator. Money returned due to time commitment of Dr. Haehner’s primary work in the lab of Dr. Craig Brater and inability to complete project with funds granted.

PUBLICATIONS

Manuscripts (peer reviewed publications)

- 1) Sprague SM, **Moe SM**. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. *American Journal of Kidney Diseases*. 1992;19:532-9.
- 2) **Moe SM**, Sprague SM. Beta 2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae. *American Journal of Physiology*. 1992;263:F540-5.
- 3) **Moe SM**, Barrett SA, Sprague SM. β_2 microglobulin stimulates osteoclastic mediated bone mineral dissolution from neonatal mouse calvariae. In: DV Cohn, C Gennari, AH Tashjian, Jr., eds. *Calcium Regulating Hormones and Bone Metabolism*. Amsterdam: Elsevier Science Publishers, 1992.
- 4) **Moe SM**, Baron JM, Coventry S, Dolan C, Umans JG. Glomerular disease and urinary Sezary cells in cutaneous T-cell lymphomas. *American Journal of Kidney Diseases*. 1993;21:545-7.
- 1) **Moe SM**, Yu BO, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. *American Journal of Kidney Diseases*. 1993;22:300-7.
- 2) **Moe SM**, Sprague SM. Uremic encephalopathy. *Clinical Nephrology*. 1994;42:251-6.
- 3) **Moe SM**, Hack BK, Cummings SA, Sprague SM. Role of IL-1 beta and prostaglandins in beta 2-microglobulin-induced bone mineral dissolution. *Kidney International*. 1995;47:587-91.
- 4) Ouseph R, Leiser JD, **Moe SM**. Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches. *Journal of the American Society of Nephrology*. 1996;7:497-505.
- 5) **Moe SM**, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. *Nephrology, Dialysis, and Transplantation*. 1998;13:1234-41.

- 6) **Moe SM**, Bailey AM. A coculture model of synoviocytes and bone for the evaluation of potential arthritis therapies. *Journal of Pharmacology and Toxicology Methods*. 1999;41:127-34.
- 7) Brophy DF, Sowinski KM, Kraus MA, **Moe SM**, Klaunig JE, Mueller BA. Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis. *Peritoneal Dialysis International*. 1999;19:534-9.
- 8) **Moe SM**, Singh GK, Bailey AM. Beta2-microglobulin induces MMP-1 but not TIMP-1 expression in human synovial fibroblasts. *Kidney International*. 2000;57:2023-34.
- 9) Jaradat M, Phillips C, Yum MN, Cushing H, **Moe S**. Acute tubulointerstitial nephritis attributable to indinavir therapy. *American Journal of Kidney Diseases*. 2000;35:E16.
- 10) Jaradat MI, Schnitzlein-Bick CT, Singh GK, **Moe SM**. β_2 -Microglobulin increases the expression of vascular cell adhesion molecule on human synovial fibroblasts. *Kidney International*. 2001;59:1951-9.
- 11) Ahmed S, O'Neill KD, Hood AF, Evan AP, **Moe SM**. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. *American Journal of Kidney Diseases*. 2001;37:1267-76.
- 12) **Moe SM**, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. *American Journal of Kidney Diseases*. 2001;38:792-802.
- 13) Chen NX, O'Neill KD, Niwa T, **Moe SM**. Signal transduction of beta2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. *Kidney International*. 2002;61(2):414-24.
- 14) **Moe SM**, O'Neill KD, Duan D, Ahmed S, Chen XN, Leapman SB, Fineberg N, Kopecky KK. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. *Kidney International*. 2002;61(2):638-47.
- 15) Russell R, Brookshire MA, Zekonis M, **Moe SM**. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. *Clinical Nephrology*. 2002;58(4):238-243.
- 16) O'Neill KD, Chen NX, Wang, M, Cocklin, R, **Moe SM**. Cellular uptake of B2M and AGE-B2M in synovial fibroblasts and macrophages. *Nephrology, Dialysis, and Transplantation*. 2003;18:46-53-8.
- 17) Chen NX, O'Neill KD, Duan D, **Moe SM**. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. *Kidney International*. 2002;62(5):1724-31.
- 18) Lindberg JS, **Moe SM**, Goodman WG, Coburn JW, Sprague SM, Lui W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. *Kidney International*. 2003;63(1):248-254.
- 19) Reslerova M, **Moe SM**. Vascular calcification in dialysis patients: pathogenesis and consequences. *American Journal of Kidney Diseases*. 2003;41(3, Suppl 1):S96-S99.
- 20) **Moe SM**, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. *Kidney International*. 2003;63(3):1003-1011.
- 21) **Moe SM**, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, Meyer C. Assessment of vascular calcification in ESRD patients using spiral CT. *Nephrology, Dialysis, and Transplantation*. 2003;18:1152-1158.

- 22) Cocklin RR, Zhang Y, Bidasee KR, O'Neill KD, Chen NX, **Moe SM**, Wang M. Identity and localization of advanced glycation end products on human B2-microglobulin using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Analytical Biochemistry*. 2003;15:322-325.
- 23) **Moe SM**, Chen NX. Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. *Pediatric Nephrology* 2003; 18:969-975.
- 24) **Moe SM**, Drüeke, T. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. *American Journal of Nephrology*. 2003; 23:369-379.
- 25) Kays, MB, Overholser BR, Mueller BA, **Moe SM**, Sowinski KM. Effects of sevelamer hydrochloride and calcium and acetate on the oral bioavailability of ciprofloxacin. *American Journal of Kidney Diseases*. 2003; 42:1253-1259.
- 26) **Moe SM**. Calcific uremic arteriolopathy: a new look at an old disorder. *NEPHSAP*, 2004; 3:77-83.
- 27) Block GA, Martin KJ, deFrancisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenpoel P, **Moe SM**, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet Hydrochloride for secondary hyperparathyroidism in patients receiving hemodialysis. *New England Journal Medicine* 2004;350:1520-1529.
- 28) **Moe SM**. Management of renal osteodystrophy in peritoneal dialysis patients. *Peritoneal Dialysis International*. 2004; 24:209-16
- 29) **Moe SM**, O'Neill KD, Reselero M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. *Nephrology, Dialysis, and Transplantation*. 2004; 19:2387-93
- 30) **Moe SM**, Chen NX. The pathophysiology of vascular calcification in chronic kidney disease. *Circulation Research* 2004; 95:560-567
- 31) **Moe SM**. Uraemic vascular calcification. *Journal of the Royal College of Physicians Edinburg*. 2004; 34:280-286
- 32) **Moe SM**, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson MS, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl *Kidney International* 2005; 67:760-771
- 33) **Moe SM**. Disorders of calcium (Ca), phosphorus (P), and magnesium (Mg): core curriculum in nephrology. *Am J Kidney Dis*. 2005; 45:213-8
- 34) **Moe SM**, Reslerova M, Ketteler M, O'Neill KD, Duan D, Koczman JJ, Westenfeld R, Jahnen-Dechent W, Chen NX. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease. *Kidney Int* 2005 67(6):2295-304
- 35) **Moe SM**, Cunningham J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. *Nephrol Dial Transplant*. 2005 20(10):2186-93.
- 36) Laclair, RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves, KL, **Moe SM**. Prevalence of calcidiol deficiency in chronic kidney disease: a cross-sectional study across latitudes in the United States. *Am J Kidney Dis*. 2005 45(6):1026-33
- 37) Friedman A, **Moe SM**. Review of the effects of omega-3 supplementation in dialysis patients. *Clin J Am Soc Neph* 2006 1:182-192.

- 38) Brosius C, Hosttter TH, Kelepouris E, Mitsnefes M, **Moe SM**, Moore MA, Smith GL, Pennathur S, Wilson PWF. AHA Science Advisory on Detection of Kidney Disease in patients with or at Increased Risk of Cardiovascular Disease. *Hypertension* 2006 48(4): 751-755 and *Circulation*. 2006 Sep 5;114(10):1083-7.
- 39) **Moe SM**, Drueke TM, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, and Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006 69:1945-1953
- 40) Friedman AN, **Moe SM**, Perkins SM, Li Y, Watkins WA. Fish consumption and omega-3 fatty acid status and determinants in chronic hemodialysis. *Am J Kidney Dis* 2006 47:1064-1071
- 41) **Moe SM**, Chertow, GM. The Case against Calcium-Based Phosphate Binders. *Clin J Am Soc Nephrol* 2006 1:697-703
- 42) Chen NX, Duan D, O'Neill KD, **Moe SM**. High Glucose Increases the Expression of Cbfa1 and BMP-2 and Enhances the Calcification of Vascular Smooth Muscle Cells. *Nephrol Dial Transplant* 2006 21:3435-3442
- 43) Chen NX, Wolisi GO, Duan D, O'Neill KD, Koczman JJ, Fang J, **Moe SM**. Cbfa1 and BMP-2 are both involved in uremic serum induced calcification in bovine vascular smooth muscle cells (BVSMC). *Kidney International* 2006 Sep;70(6):1046-53
- 44) Chen NX, O'Neill K, Chen X, Duan D, Wang E, and **Moe SM**. Fetuin-A uptake in bovine vascular smooth muscle cells (BVSMC) is calcium dependent and mediated by annexins. *Am J Physiol Renal Physiol* 2006
- 45) **Moe SM**. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. *Eur J Clin Invest* 2006 Suppl 2:51-62.
- 46) **Fadem SZ Moe SM**. Management of Chronic Kidney Disease – Mineral Bone Disorder. *Advances Chronic Kidney Dis*, in press 2007
- 47) **Moe SM**, Drueke T, Lameire N, Eknoyan G, Chronic Kidney Disease- Mineral Bone Disorder: A new paradigm. *Advances Chronic Kidney Dis*, in press 2007
- 48) Chertow GM, Pupim LB, Block G, Correa-Rotter R, Drueke T, Floege J, Goodman W, London G, Mahaffey K, **Moe SM**, Wheeler D, Albizem M, Olson K, Klassen P, Parfrey. EVOLVE (**E**valuation **O**f Cinacalcet Therapy to **L**ower Cardio**V**ascular **E**vents)TM. *Rationale and Design of a Randomized Clinical Trial*. Submitted.

Textbooks

- 1) Sprague SM, **Moe SM**. Neurologic accompaniments of renal failure. In: PJ Vinken, GW Bruyn, HB Klawans, eds. *Handbook of Clinical Neurology*. Amsterdam: North Holland Publishing Co. 1993;19(63):503-521.
- 2) Associate Editor, Mineral Metabolism, Yearbook of Nephrology 1999. Editor Steve Schwab, Mosby, Inc. St Louis, MO, 1999.
- 3) Associate Editor, Mineral Metabolism, Yearbook of Nephrology 2000. Editor Steve Schwab, Mosby, Inc. St Louis, MO, 2000.
- 4) **Moe SM**. Disorders of Phosphorus Metabolism: In Handbook of Internal Medicine, for Palm Pilots. Robert Alpern, Editor. PocketMedicine.com, Inc., released 2001.
- 5) **Moe SM**. Calcium, Phosphorus, and Vitamin D Metabolism in renal diseases and chronic renal failure. In Nutritional Management of Renal Diseases, 2nd Edition. Edited by JD Koppple and SG Massry., October 2003.

- 6) Linberg JS, **Moe SM**. Co-Editor, Seminars in Nephrology, Special Edition on Mineral Metabolism, January 2004.
- 7) Chen, XC, **Moe, SM**. *Actualités Néphrologiques Jean Hamburger*. Uremic vascular calcification. Edited by P. Lesavre, T. Drüeke, C. Legendre, P. Niaudet. Flammarion Médecine-Sciences, Paris, France, 2004.
- 8) **Moe SM**. Renal Osteodystrophy. In *Chronic Kidney Disease: Dialysis and Transplantation*, 2nd edition. Edited by BJK Pereira, M Sayegh, P Blake. Elsevier Saunders, Philadelphia, PA, 2004
- 9) **Moe SM** Management of hyperphosphatemia in Chronic Kidney Disease, in *Handbook of mineral disorders*, Ed by C Hsu, in press
- 10) Drueke TM, **Moe SM**, Langman C “Treatment of Renal Osteodystrophy” in *Disorder of Bone and Mineral Disease* published by KDIGO, 2006
- 11) **Moe SM**. Disorders of Phosphorus Metabolism: In *Handbook of Internal Medicine*, for Palm Pilots. Robert Alpern, Editor. PocketMedicine.com, Inc., in revision, 2006.
- 12) **Moe SM**, Sprague SM. Pathogenesis of CKD-MBD and Renal Osteodystrophy in *The Kidney*, ed. B. Brenner, in press.
- 13) **Moe, SM**, Fadem, SF. *Advances in Chronic Kidney Disease: journal guest editor “CKD-MBD”*, January 2007

Invited Reviews/Editorials:

- 1) **Moe SM**, Sprague SM. Evaluating and treating renal osteodystrophy. *Clinical Comment*. 1991;7:5-8.
- 2) Sprague SM, **Moe SM**. The clinical manifestations and pathophysiology of β_2 -microglobulin amyloidosis. *Seminars in Nephrology*. 1996;9:360-369.
- 3) **Moe SM**. Dialysis Amyloid. In: C van Ypersele, T Drueke, eds. *Amyloid*. 1997;4:142. (book review)
- 4) **Moe SM**. The treatment of steroid-induced bone loss in transplantation. *Current Opinion in Nephrology and Hypertension*. 1997;6:544-549.
- 5) **Moe SM**. Questions in Dialysis-The use of oral bisphosphonates in advanced renal failure. *Seminars in Dialysis*. 1998;11(5):318.
- 6) Lindberg JS, **Moe SM**. Osteoporosis in ESRD. *Seminars in Nephrology*. 1999;19:115-122.
- 7) Lindberg JS, **Moe SM**, Stehman-Breen C. Osteoporosis in ESRD. *Dialysis and Transplantation*. 2000;21:37-42.
- 8) **Moe SM**, Chen NX. The role of the synovium in β_2 -microglobulin amyloidosis. *Seminars in Dialysis*. 2001;14:127-130.
- 9) Jaradat M, **Moe SM**. The interaction of β_2 -microglobulin with dialysis membranes. *Seminars in Dialysis*. 2001;14:131-134.
- 10) **Moe, SM**. Current issues in the management of secondary hyperparathyroidism/bone disease. *Peritoneal Dialysis International*. 2001;21:S241-S246.
- 11) **Moe, SM**. The impact of HIPAA on human subjects research. *Dialysis Times*. 2002;9(3):2-8.
- 12) **Moe, SM**, Chen, NX. Vascular calcification in end stage renal disease. *Clinical Calcium*. 2002;12(10):51-56.

- 13) Chen, NX, **Moe, SM**. Arterial calcification in diabetes. *Current Diabetes Report*. 2003; 3(1): 28-32.
- 14) Chen, NX, **Moe, SM**. Vascular calcification in chronic kidney disease. *Seminars in Nephrology*. 2004, 24:61-68.
- 15) **Moe, SM**, Drüeke, T. Controversies in bone and mineral metabolism in CKD: a bridge to improving healthcare outcomes and quality of life. *American Journal of Kidney Diseases*. 2004;3:552-7.
- 16) Drüeke, T, **Moe, SM**. Disturbances of bone and mineral metabolism in chronic kidney disease: an international initiative to improve diagnosis and treatment. *Nephrology, Dialysis, Transplantation*. 2004; 19(3):534-536
- 17) **Moe, SM**. Cinacalcet hydrochloride. Guest commentary for *Drugs*. 2004, In press.
- 18) **Moe, SM**. Uremic vasculopathy. *Seminars in Nephrology*, 2004; 24(5): 413-416
- 19) **Moe SM**, Chen NX. Vascular calcification. *Nephrology Round, Harvard University*. 2004,
- 20) Leapman, SB, **Moe, SM**. Protecting the Patient: Human Subjects and Medical Research. *Research Ethics and Medical Education Virtual Mentor, American Medical Association*. November 2004 [HTTP://www.ama-assn.org/ama/pub/category/13260.html](http://www.ama-assn.org/ama/pub/category/13260.html),
- 21) **Moe SM**, Chen NX. Inflammation and vascular calcification. *Blood Purification*. 2005; 23: 64-71
- 22) Chertow GM, **Moe SM**. Calcification or Classification? *Journal of the American Society of Nephrology*. 2005; 16:293-96
- 23) Wolisi GO, **Moe SM**. The role of vitamin D in vascular calcification. *Seminars in Nephrology* 2005;18:307-14.
- 24) **Moe SM**. Vascular calcification: Hardening of the evidence. *Kidney Int*. 2006 Nov;70(9):1535-7.
- 25) **Moe SM**: Treating CKD-MBD. *Therapeutic Apheresis*, in press 2007
- 26) **Moe SM**, Drueke T: KDIGO: Bone and Mineral Initiative. *Clinical J Amer Soc Nephrology*, in press 2007